NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Free peptide testing

Ordered peptides from HXNet? Mail in a sample (US only) and let us test it.

Test my supply
+4 more ↓
71%
Finnrick rating
#275 of 457 ranked vendors
141 of 170 classifiable tests passed
methodology · Purity focus
Finnrick analysis

HXNet's purity-focus evidence is broad and current but dispersed, with GHK-Cu and Tirzepatide carrying the stronger signal. Tesamorelin and TB-500 are the weaker lanes, driven by purity dips and large fill swings; recent results show some recovery, but uneven batch IDs limit traceability.

methodology →
vendor intelligence report
Vendor Intelligence Report: HXNet

Corporate records anchor HXNet to Hebei Xunou while the old domain is dead and sales have shifted into forum/Pastebin lanes. The report follows the HXTNT/KIRA/KARA reseller split, Janoshik chain-of-custody gaps, and documented refund/contamination disputes.

30 pages9 risk factors assessed2 Jul 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.04
90%
13
2
Tirzepatide
$0.35
89%
52
3
Retatrutide
$0.60
82%
47
5
Semaglutide
$1.00
77%
5
6
BPC-157
$0.60
64%
9
7
PT-141
$0.50
62%
2
8
Cagrilintide
$1.76
62%
15
9
Tesamorelin
$1.80
53%
12
10
CJC-1295
-
49%
5
11
Sermorelin
-
49%
3
12
TB-500
$1.36
43%
5
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%23 Apr 2026: 67%28 Apr 2026: 67%28 Apr 2026: 67%28 Apr 2026: 68%30 Apr 2026: 68%2 May 2026: 68%2 May 2026: 68%8 May 2026: 68%8 May 2026: 68%11 May 2026: 68%11 May 2026: 68%13 May 2026: 68%13 May 2026: 69%13 May 2026: 69%15 May 2026: 69%15 May 2026: 69%18 May 2026: 69%21 May 2026: 69%27 May 2026: 69%2 Jun 2026: 69%2 Jun 2026: 69%2 Jun 2026: 69%2 Jun 2026: 69%4 Jun 2026: 69%6 Jun 2026: 69%6 Jun 2026: 70%12 Jun 2026: 70%24 Jun 2026: 70%26 Jun 2026: 70%1 Jul 2026: 70%13 Jul 2026: 70%13 Jul 2026: 70%20 Jul 2026: 70%9 Aug 2026: 70%12 Aug 2026: 70%15 Aug 2026: 71%24 Sep 2026: 71%24 Sep 2026: 71%24 Sep 2026: 71%24 Sep 2026: 71%2 Oct 2026: current 71%67%70%71%Apr 26Oct 26
Free peptide testing

Ordered peptides from HXNet? Mail in a sample (US only) and let us test it.

Test my supply
HXNet test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
24 Sep 2026
Pass
GHK-Cu
lab nameView COA
24 Sep 2026
Pass
GHK-Cu
lab nameView COA
24 Sep 2026
Pass
CJC-1295 (No DAC)
lab nameView COA
24 Sep 2026
Pass
Retatrutide
lab nameView COA
15 Aug 2026
Pass
Sermorelin
lab nameView COA
12 Aug 2026
Pass
Tirzepatide
lab nameView COA
9 Aug 2026
Pass
Tesamorelin
lab nameView COA
20 Jul 2026
Pass
Retatrutide
lab nameView COA
13 Jul 2026
Pass
Tirzepatide
lab nameView COA
13 Jul 2026
Pass
Retatrutide
lab nameView COA
1-10 of 173

About HXNet test results from Finnrick

HXNet is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 12 peptides and 173 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible HXNet peptides in this dataset are Tirzepatide (52 tests), Semaglutide (5 tests) and BPC-157 (9 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 173 recent tests.

Corrections
No corrections.
Free peptide testing

Ordered peptides from HXNet? Mail in a sample (US only) and let us test it.

Test my supply